share_log

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target

Benzinga ·  Nov 1 12:33

RBC Capital analyst Gregory Renza reiterates Alnylam Pharmaceuticals (NASDAQ:AGIO) with a Outperform and maintains $55 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment